ProCE Banner Activity

FINCH 1: 52-Wk Results of Filgotinib in Patients With Rheumatoid Arthritis With Inadequate Response to Methotrexate

Slideset Download
Conference Coverage
Efficacy of add-on therapy with JAK1 inhibitor filgotinib sustained through Week 52 with no new safety signals in patients with rheumatoid arthritis and inadequate response to methotrexate.

Released: July 13, 2020

Expiration: July 12, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AbbVie Inc.

Gilead Sciences, Inc.